Last reviewed · How we verify
NCT06276036
Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.
NA trial testing Identification of specific markers in Cytopenia in 53 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Meyer Children's Hospital IRCCS |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 53 |
| Start date | 23 July 2019 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 6 locations across Belgium, Italy, United States |
Drugs / interventions tested
- Identification of specific markers
Conditions studied
- Cytopenia — all drugs for Cytopenia →
Sponsor
Meyer Children's Hospital IRCCS
Who can join
Adults 1 to 17, any sex, with Cytopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopenias has not yet been fully elucidated. Moreover, conventionally employed therapeutic strategies often fail, leading to increased healthcare costs, high morbidity, and even mortality. Therefore, there is a need to establish clinical guidelines for diagnosis and to identify early biomarkers capable of identifying individuals responsive to therapy. Thus, a systematic approach to the study of such pathologies will allow for the identification of early biomarkers and facilitate the development of targeted therapeutic strategies
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06276036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cytopenia
Currently open trials in the same condition.
- NCT06802146 — Early Intervention in High Risk CCUS · EARLY_PHASE1 · recruiting
- NCT04873102 — Danazol for Treatment of Cytopenias in Patients With Cirrhosis · Phase 2 · recruiting
- NCT06285825 — A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia · Phase 2 · recruiting
- NCT06430788 — A Study of Emapalumab for Pediatric Aplastic Anemia · Phase 2 · recruiting
- NCT05236764 — Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion · NA · active not recruiting
Other Meyer Children's Hospital IRCCS trials
Trials by the same sponsor.
- NCT07412782 — REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD) · NA · recruiting
- NCT07363304 — Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People Wi · recruiting
- NCT07412769 — ASMact: Study on Management of Bronchial Asthma · recruiting
- NCT07468461 — CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome · recruiting
- NCT07348263 — EFESO: Study on Juvenile Onset Eosinophilic Fasciitis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06276036 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Meyer Children's Hospital IRCCS
- Last refreshed: 29 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06276036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing